Search In this Thesis
   Search In this Thesis  
العنوان
Serum Osteopontin as a Blood Biomarker in
Relapsing Remitting Multiple Sclerosis
Egyptian Patients /
المؤلف
Mohammed, Dina Lotfy.
هيئة الاعداد
باحث / دينا لطفي محمد
مشرف / هناء أحمد عامر
مشرف / رانيه احمد ابوشادى
مشرف / نعمة لطفي محمد
تاريخ النشر
2022.
عدد الصفحات
131 P. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
علم الأعصاب السريري
تاريخ الإجازة
1/1/2022
مكان الإجازة
جامعة عين شمس - كلية الطب - قسم الباثولوجيا الاكلينيكية
الفهرس
Only 14 pages are availabe for public view

from 131

from 131

Abstract

M
ultiple sclerosis (MS) is an important immune- mediated disease of the central nervous system. This disease results in inflammation, demyelination and axonal damage leading to degeneration of the neurons. It affects more than 2.5 million people worldwide, leading to disability in young adults.
There are four clinical subtypes, clinically isolated syndrome (CIS); relapsing-remitting MS (RRMS); the most common type of MS, primary progressive MS (PPMS); and secondary progressive MS (SPMS).
Early diagnosis of MS is necessary for better control of the disease and to reduce its progression. Investigations as Magnetic Resonance Imaging (MRI), visual evoked potential, blood and cerebrospinal fluid (CSF) analysis are the corner stone helping in the evaluation of the case. Identifying a reliable biomarker may accelerate diagnosis of multiple sclerosis (MS) and lead to early management of the disease.
Osteopontin (OPN) is an extracellular matrix protein and is considered as an interesting biomarker because of its role in the pathophysiology of several inflammatory, degenerative, autoimmune, and oncologic diseases.
The aim of this study is to evaluate Osteopontin as a blood biomarker in Relapsing- Remitting Multiple Sclerosis Egyptian patients and correlate it with disease activity.
Our study was a case-control study performed on a group of patients diagnosed as RRMS by Mac Donalds criteria 2017.
This study is a case-control study, conducted on 90 individuals diagnosed as RRMS by Mac Donalds criteria 2017.Subjects enrolled in the study were classified into two groups.
group І: Control group (n=30): It involves age and sex matched healthy individuals.
group ІІ: Patient group (n=60): It involves patients with RRMS.
group II is subdivided into 2 subgroups:
• group IIa: (n=30): Patients in remission. They were 26 females and 4 males. Their ages ranged from 20 to 53 years with the mean ± SD was 32.2 ± 8.17 as shown in (table 5).
• group IIb: (n=30): Patients in relapse before receiving methyl-prednisolone. They were 27 females and 3 males. Their ages ranged from 20 to 54 years with the mean ± SD was 33.4± 8.17 as shown in (table 5).
All groups were homogeneous in the terms of size and demographic characteristics with no significant differences. But there was statistically significant higher OPN level in group II than group I (P-value < 0.001).
OPN levels were significantly higher in patients groups compared to control group (p-value < 0.001). Using ROC curve it can be used to discriminate between group I and group II at a cutoff level of > 8ng/ml, with 88.33% sensitivity, 100% specificity, 100% PPV and 81.1% NPV.
In the present study, there was a statistically significant difference between group I and group II as regard lymphocyte count (p-value < 0.05) where group II reported lower levels of lymphocyte count.
Comparison between group IIa and group IIb, in our study, shows no statistically significant differences between both groups as regard sociodemographic, clinical and laboratory data (p-value > 0.05) expect for EDSS that was significantly higher in group IIb (p-value < 0.05). In our study, we found a significant correlation between OPN level and AST level (p-value < 0.05).

CONCLUSION
S
erum OPN level increased in MS patients. It could be hypothesized that its level increases as a pro-inflammatory biomarker not specific for MS patients. OPN may not be a specific marker for MS. Our data does not support a role for circulating OPN levels as a biomarker for disease activity, but also does not rule out a potential role for OPN measurement in the cerebrospinal fluid alone or in association with other biomarkers.

RECOMMENDATIONS
O
ur recommendations for the future studies on OPN is to work on larger scale of MS patients considering the other types of all disease forms. Study of OPN in CSF or in combination with other biomarker may be of significant value